Precision Medicine in Angelman Syndrome

Area of Science:

• Neurogenetics
• Developmental disorders
• Rare diseases

Background:

• Angelman syndrome (AS) is a rare neurogenetic disorder.
• It results from the loss of function of the UBE3A gene on the maternal allele.
• Key clinical features include severe neurodevelopmental delay, epilepsy, sleep disturbances, and behavioral issues.

Purpose of the Study:

• To provide an overview of the current clinical research landscape for Angelman syndrome.
• To discuss emerging therapeutic approaches being investigated for AS.
• To highlight the progression from symptomatic treatments to novel genetic therapies.

Main Methods:

• Review of current clinical research on Angelman syndrome.
• Analysis of ongoing and completed clinical trials.
• Discussion of therapeutic strategies targeting mRNA expression.

Main Results:

• Conventional treatments for AS primarily focus on symptomatic and supportive care, including antiseizure medications.
• Novel therapeutic strategies are being developed to target mRNA expression, aiming to restore UBE3A function.
• Several clinical trials are actively investigating these new approaches.

Conclusions:

• The therapeutic landscape for Angelman syndrome is evolving towards disease-modifying treatments.
• Targeting mRNA expression represents a promising avenue for future AS therapies.
• Ongoing clinical research is crucial for advancing treatment options for individuals with Angelman syndrome.